A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer

Published:2018-08 Issue:8 Volume:41 Page:772-776
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Cardin Dana B.,Thota Ramya,Goff Laura W.,Berlin Jordan D.,Jones Clyde M.,Ayers Gregory D.,Whisenant Jennifer G.,Chan Emily

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference39 articles.

1. Cancer statistics, 2016;Miller;CA Cancer J Clin,2016

2. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

4. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial;Oettle;J Clin Oncol,2014

5. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma;Yanagimoto;Cancer Chemother Pharmacol,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study;Frontiers in Immunology;2024-01-10

2. Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor Microenvironment;Cancers;2023-10-01

3. Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?—A systematic review;Journal of Cancer Research and Clinical Oncology;2023-03-26

4. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice;International Journal of Molecular Sciences;2023-03-06

5. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review;Cancer Treatment Reviews;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3